Key Clinical Message: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many features in common and may coincide in the same patient. Timely diagnosis and management of visceral leishmaniasis could save patients from unnecessary toxic treatment.

Abstract: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many clinical features in common and may coexist in the same patient. Visceral leishmaniasis should be promptly ruled out in patients coming from endemic areas before starting immunosuppressive therapy for hemophagocytic lymphohistiocytosis. The mainstay treatment, in this case, is anti-leishmania medications preferably liposomal amphotericin-B.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160431PMC
http://dx.doi.org/10.1002/ccr3.7309DOI Listing

Publication Analysis

Top Keywords

visceral leishmaniasis
20
hemophagocytic lymphohistiocytosis
16
leishmaniasis hemophagocytic
8
lymphohistiocytosis share
8
features common
8
visceral
5
leishmaniasis complicated
4
hemophagocytic
4
complicated hemophagocytic
4
lymphohistiocytosis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!